Physician profile
Joseph E Spahr
NPI 1659432235
$5,582.09
in general payments reported to CMS, 2019-2025
21 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,235 · 2020: $407 · 2021: $2,096 · 2022: $424 · 2023: $96.18 · 2024: $24.92 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $400.78 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $4,104.55 | 2019-2021 | |
| Tactile Systems Technology INC | $386.08 | 2019-2022 | |
| Boston Scientific Corporation | $288.90 | 2020-2022 | |
| Tempus Ai, INC | $167.81 | 2025 | Xt Cdx |
| E.R. Squibb & Sons, L.L.C. | $109.75 | 2021-2025 | Opdivo |
| Venclose INC. | $82.26 | 2020 | |
| Bard Peripheral Vascular, INC. | $79.09 | 2021-2022 | |
| Merz North America, INC. | $62.35 | 2020 | |
| Janssen Scientific Affairs, LLC | $47.34 | 2022-2024 | Imbruvica, Erleada, Darzalex |
| Astrazeneca Pharmaceuticals LP | $33.95 | 2023 | |
| Genentech USA, INC. | $27.62 | 2022-2023 | Gavreto, Alecensa, Tecentriq |
| Myriad Genetic Laboratories, INC. | $25.79 | 2025 | Myrisk |
| Beigene USA, INC. | $24.94 | 2023 | Brukinsa |
| Daiichi Sankyo INC. | $23.54 | 2023 | Enhertu |
| Biocompatibles, INC. | $21.58 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $21.58 | 2025 | Besremi |
| Pfizer INC. | $21.40 | 2021 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Kyowa Kirin, INC. | $19.93 | 2025 | |
| Merck Sharp & Dohme LLC | $13.63 | 2025 | Keytruda |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Spahr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.